0.00Open0.10Pre Close0 Volume199 Open Interest1.00Strike Price0.00Turnover128.24%IV11.68%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.5535Delta1.2150Gamma7.88Leverage Ratio-0.0027Theta0.0003Rho4.36Eff Leverage0.0010Vega
CytomX Stock Discussion
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
CytomX Therapeutics, Inc. (Nasdaq: CTMX) unveiled positive initial data from its ongoing CX-904 Phase 1a dose escalation clinical study. This pivotal study is centered around CX-904, an investigational PROBODY® T-cell engager that is both masked and conditionally activated, designed to target t...
No comment yet